ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

SNG Synairgen Plc

4.52
-0.235 (-4.94%)
24 Jul 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Synairgen Plc LSE:SNG London Ordinary Share GB00B0381Z20 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.235 -4.94% 4.52 4.35 4.69 4.75 4.36 4.75 212,429 16:35:15
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 0 -17.65M -0.0876 -0.50 9.58M
Synairgen Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker SNG. The last closing price for Synairgen was 4.76p. Over the last year, Synairgen shares have traded in a share price range of 3.65p to 10.62p.

Synairgen currently has 201,374,975 shares in issue. The market capitalisation of Synairgen is £9.58 million. Synairgen has a price to earnings ratio (PE ratio) of -0.50.

Synairgen Share Discussion Threads

Showing 6326 to 6350 of 99175 messages
Chat Pages: Latest  259  258  257  256  255  254  253  252  251  250  249  248  Older
DateSubjectAuthorDiscuss
05/5/2020
07:56
It’ll be interesting to see if our new >£100m mkt cap does actually generate more activity from fund managers as hoped.
wetdream
05/5/2020
07:40
Maybe we will see your predicted 80p - 100p today Nobby!
lovewinshatelosses
05/5/2020
07:38
Hi peanut. I would be surprised if that happened before results, but it is possible I guess.
lovewinshatelosses
05/5/2020
07:35
First MM has opened 73-78...
nobbygnome
05/5/2020
07:30
BATM Advanced Comm
BATM Launches Antibody Tests for COVID-19
RNS Number : 8843L
BATM Advanced Communications Ld
05 May 2020

whites123
05/5/2020
07:30
More news filtering out into other countries



Inside the 'breakthrough' drug that could transform coronavirus fight

BBC Panorama has been allowed inside a UK coronavirus drugs trial for the first time.

The SNG-001 drug, being developed by Synairgen, prepares the body for a viral attack by stimulating the immune response in the lungs of asthma and chronic lung disease patients.

It is hoped the treatment will help coronavirus patients and prevent the most severe cases from requiring intensive care and ventilators.

Panorama has spoken to those involved in a trial at University Hospital Southampton.

Richard Marsden, the CEO of Synairgen, said: “Our drug is a special formulation of interferon beta that we deliver directly to the airways when the virus is there.

makendon
05/5/2020
07:28
Is there a chance of a tie up here pre results or will government agency's have first rights pre or post results? Sorry may already of been covered.
peanut100
05/5/2020
07:26
Hi Nobby. No particular reason, just a gut feeling (so safely ignored!)
lovewinshatelosses
05/5/2020
07:23
Why were you expecting an RNS today in particular?
nobbygnome
05/5/2020
07:17
Only mildly; it will come in due course! If this dips back into the previous range today, I will make another small top up I think.
lovewinshatelosses
05/5/2020
07:14
lovewinshatelosses - I suspect you will be very disappointed
equalibrium
05/5/2020
06:35
Who else is eagerly looking forward to seeing if we have an RNS shortly and the reaction of the share price during those first few minutes of the opening bell regardless? I must confess to a childish thrill myself, even though this is not one of my trading stocks! GLA.
lovewinshatelosses
05/5/2020
06:24
Some overnight Pharma news if people care:

[-] BERGENBIO - Offering Prices 13.3m Shares at NOK37.50/Share. Offering via Arctic Securities, Carnegie, DNB Markets. Meteva AS, represented on the board of directors by Sveinung Hole, was allocated 1.7m shares; to own 22m shares, equal to 25.32%. Expected trading date May 7. Price represents 14.68% discount to last close. 73.3m shares outstanding (44.8m-share float)

[=] MEDIVIR - Receives Orphan drug designation from U.S. FDA for Treatment of Hepatocellular Carcinoma

[=] NOVOZYMES - Agreed to purchase 765,000 B shares for DKK 257.8m from Novo Holdings as part of its 2020 share repurchase programme.

[=] ROCHE - U.K. in talks with Roche about mass roll-out of antibody tests.

[=] SANOFI - and Regeneron said Libtayo (cemiplimab) shows clinically-meaningful and durable responses in second-line advanced basal cell carcinoma

[=] OERLIKON - Q1 Sales CHF529mn vs cons CHF526mn, EBITDA CHF58mn vs cons CHF51mn, Orders CHF477mn vs cons CHF518mn (1Q group order intake, sales and Ebitda were negatively impacted by coronavirus pandemic due to the extended shutdowns in China and the beginning of lockdowns in Europe), Order backlog CHF545mn, withdrawing our guidance for 2020.

markinvestor
05/5/2020
02:01
Yes bobaxe1 but the research is being paid for by the government !

This is going over £2 soon 🚀🚀🚀

strongbuy
05/5/2020
01:10
Two years of high risk research trial costs good luck
bobaxe1
05/5/2020
00:06
80p first thing:))
bmnsa
04/5/2020
23:18
Huge that RM was interviewed and noted as MD of Synairgen. Commercially massive that BBC gave him that exposure, I wonder why???
tburns
04/5/2020
22:19
Well the ONLY person from a commercial company allowed onto the programme to speak
about their product going forward was Richard from Synairgen. End of !

GL ALL

westmoreland lad
04/5/2020
22:04
Wondered how long that would take :)

The original:

and part of the conclusion:

'In conclusion, this is the first report of a (human) monoclonal antibody that neutralizes SARS-CoV-2. 47D11 binds a conserved epitope on the spike RBD explaining its ability to cross-neutralize SARS-CoV and SARS-CoV-2, using a mechanism that is independent of receptor-binding inhibition. This antibody will be useful for development of antigen detection tests and serological assays targeting SARS-CoV-2. Neutralizing antibodies can alter the course of infection in the infected host supporting virus clearance or protect an uninfected host that is exposed to the virus4. Hence, this antibody—either alone or in combination—offers the potential to prevent and/or treat COVID-19, and possibly also other future emerging diseases in humans caused by viruses from the Sarbecovirus subgenus.'

supernumerary
04/5/2020
21:56
Scientists Create Antibody That Defeats Coronavirus in Lab
euclid5
04/5/2020
21:54
>> bobaxe

I would say, based on the script from the BBC release yesterday ——- “1 out of 75 from the 10 hospitals around Britain”

makendon
04/5/2020
21:49
Just watched Panorama having recorded it earlier. What a remarkable recovery by the old dear after a few puffs on the SNG trial nebuliser ;-) 🃏

Yes of course they didn't mention it might have been the placebo as far as they would have known lol!

Results in June but the whole thing was typical BBC confused reporting and that may have been referring to other trials mentioned, not clear!

However although the reporting was all over the place it's all good publicity for Synairgen and their inhaled interferon beta trial.

bountyhunter
04/5/2020
21:47
Good post cookie just catching up. Good to see our guys in the flesh on BBC even though it wasn't in depth, the lady was quite I'll looked like she was on the mend already. So one out of 100 I would say has recovered lol
bobaxe1
04/5/2020
21:46
Apologies I see that's already been posted.
tickboo
04/5/2020
21:44
Courtesy of mcmcdonald on LSE but the fact she'd take it at home tells me it helped her (assuming it wasn't placebo!). https://www.bbc.co.uk/news/health-52504409
tickboo
Chat Pages: Latest  259  258  257  256  255  254  253  252  251  250  249  248  Older